These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 498705)

  • 21. Amikacin concentrations in serum and blister fluid in healthy volunteers and in patients with renal impairment.
    Lanao JM; Navarro AS; Dominguez-Gil A; Tabernero JM; Rodriguez IC; Gonzalez Lopez A
    J Antimicrob Chemother; 1983 Nov; 12(5):481-8. PubMed ID: 6671925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amikacin pharmacokinetics in young men with pneumonia.
    Bauer LA; Blouin RA
    Clin Pharm; 1982; 1(4):353-5. PubMed ID: 7185529
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.
    Yasuhara H; Kobayashi S; Sakamoto K; Kamijo K
    J Clin Pharmacol; 1982; 22(8-9):403-9. PubMed ID: 7130429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increase of amikacin half-life during therapy in patients with renal insufficiency.
    Blaser J; Rüttimann S; Bhend H; Lüthy R
    Antimicrob Agents Chemother; 1983 Jun; 23(6):888-91. PubMed ID: 6614893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacology of amikacin in humans.
    Bodey GP; Valdivieso M; Feld R; Rodriguez V
    Antimicrob Agents Chemother; 1974 May; 5(5):508-12. PubMed ID: 4462465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Absorption, excretion and distribution of amikacin following intravenous drip infusion. Intravenous drip infusion, one shot intravenous injection and intramuscular administration of amikacin in dogs, rabbits and rats].
    Matsumoto H; Ochiai K; Nakajima A; Matsuzaki M
    Jpn J Antibiot; 1982 Aug; 35(8):2034-46. PubMed ID: 7154249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
    Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
    J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amikacin: pharmacology, indications and cautions for use, and dose recommendations.
    Philips JB; Cassady G
    Semin Perinatol; 1982 Apr; 6(2):166-71. PubMed ID: 7048537
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacokinetics of Amikacin (BB-K8) in patients with normal or impaired renal function.
    Lanao JM; Domínguez-Gil A; Tabernero JM; De Castro S
    Int J Clin Pharmacol Biopharm; 1979 Apr; 17(4):171-5. PubMed ID: 447438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amikacin pharmacokinetics in the therapy of childhood urinary tract infection.
    Khan AJ; Evans HE; Jhaveri R; Chang CT; Hochstein L
    Pediatrics; 1976 Dec; 58(6):873-6. PubMed ID: 995517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Fundamental and clinical studies on intravenous drip infusion of dibekacin in the pediatric field].
    Motohiro T; Tanaka K; Koga T; Shimada Y; Nishiyama T; Ishimoto K; Tominaga K; Yamashita F; Sakaguchi Y; Kimura K
    Jpn J Antibiot; 1985 Aug; 38(8):2068-86. PubMed ID: 4079001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of ascites on the pharmacokinetics of amikacin.
    Lanao JM; Dominguez-Gil A; Macias JG; Diez JL; Nieto MJ
    Int J Clin Pharmacol Ther Toxicol; 1980; 18(2):57-61. PubMed ID: 7372376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ototoxicity and pharmacokinetically determined dosages of amikacin in granulocytopenic cancer patients.
    Danhauer FJ; Fortner CL; Schimpff SC; deJongh CA; Wesley MN; Wiernik PH
    Clin Pharm; 1982; 1(6):539-43. PubMed ID: 7185540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maternal-fetal pharmacological activity of amikacin.
    Bernard B; Abate M; Thielen PF; Attar H; Ballard CA; Wehrle PF
    J Infect Dis; 1977 Jun; 135(6):925-32. PubMed ID: 864287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical application of amikacin dosage based upon lean body mass in patients with different renal function.
    Wagenvoort JH; Fieren MW; Goessens WH; Michel MF
    Chemotherapy; 1984; 30(2):69-75. PubMed ID: 6697814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of amikacin in patients with impaired renal function.
    McHenry MC; Wagner JG; Hall PM; Vidt DG; Gavan TL
    J Infect Dis; 1976 Nov; 134 SUPPL():S343-8. PubMed ID: 993627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay.
    Plantier J; Forrey AW; O'Neill MA; Blair AD; Christopher TG; Cutler RE
    J Infect Dis; 1976 Nov; 134 SUPPL():S323-30. PubMed ID: 993625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amikacin pharmacokinetics in morbidly obese patients.
    Bauer LA; Blouin RA; Griffen WO; Record KE; Bell RM
    Am J Hosp Pharm; 1980 Apr; 37(4):519-22. PubMed ID: 7377215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amikacin levels in the human biliary tract.
    LeFrock JL; Schell RF; Siskind S; Carr BB
    J Clin Pharmacol; 1984; 24(5-6):247-54. PubMed ID: 6747021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics of amikacin in dogs.
    Baggot JD; Ling GV; Chatfield RC
    Am J Vet Res; 1985 Aug; 46(8):1793-6. PubMed ID: 4037511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.